Browse Studies — Arctuva

Phase 2

Randomized Phase II Trial of 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastati…

Metastatic Colorectal Cancer (CRC)

Estimated

~$10 – $6,250

The Methodist Hospital Research InstituteNCT06887218

Phase 1

Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)

This is a phase I/IIA, first-in-human (FIH), two-part, open-label, multicenter study to characterize the safety, tolerability profile, and clinical efficacy of…

Unresectable Metastatic Colorectal CancerUnresectable Locally Advanced Colorectal Cancer

Estimated

~$10 – $8,750

Brenus PharmaNCT06934538

Phase 1

An Open-label, Phase Ib Study to Assess the Safety and Clinical Activity of CYAD-101 Administered Concurrently With FOLFOX Chemotherapy, Followed by Pembrolizumab Treatment, in Patients With Metastatic Colorectal Cancer

The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer admi…

Unresectable Metastatic Colorectal Cancer

Estimated

~$10 – $7,500

Celyad Oncology SANCT04991948